Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance.

ABSTRACT: Historically, treatment of patients with cancer using chemotherapeutic agents has been associated with debilitating and systemic toxicities, poor bioavailability, and unfavorable pharmacokinetics. Nanotechnology-based drug delivery systems, on the other hand, can specifically target cancer cells while avoiding their healthy neighbors, avoid rapid clearance from the body, and be administered without toxic solvents. They hold immense potential in addressing all of these issues, which has hampered further development of chemotherapeutics. Furthermore, such drug delivery systems will lead to cancer therapeutic modalities that are not only less toxic to the patient but also significantly more efficacious. In addition to established therapeutic modes of action, nanomaterials are opening up entir

SUBMITTER: Zamboni WC 

PROVIDER: S-EPMC3916007 | biostudies-literature | 2012 Jun

REPOSITORIES: biostudies-literature